- Home
- HYI vs NRXP Comparison
HYI vs NRXP Comparison
Compare HYI & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HYI | NRXP |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.2M | 153.2M |
| IPO Year | 2010 | 2017 |
Fundamental Metrics
Financial Performance| Metric | HYI | NRXP |
|---|---|---|
| Price | $10.32 | $3.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $38.25 |
| AVG Volume (30 Days) | 43.7K | ★ 1.0M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 9.59% | N/A |
| EPS Growth | N/A | ★ 69.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,225,000.00 |
| Revenue This Year | N/A | $2,547.84 |
| Revenue Next Year | N/A | $1,591.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.30 | $1.65 |
| 52 Week High | $12.12 | $5.06 |
Technical Indicators
Market Signals| Indicator | HYI | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 34.48 | 48.13 |
| Support Level | N/A | $3.45 |
| Resistance Level | $10.66 | $3.62 |
| Average True Range (ATR) | 0.06 | 0.20 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 10.34 | 61.67 |
Price Performance
Historical ComparisonAbout HYI Western Asset High Yield Defined Opportunity Fund Inc.
Western Asset High Yield Defined Opps. is a non-diversified, limited-term, closed-end management investment company. The company's investment objective is to provide high income and seek capital appreciation. The fund invests a majority of its net assets in a portfolio of high-yield corporate fixed-income securities issued or originated by U.S. or foreign public or private corporations and other business entities, with varying maturities.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.